Frédérique Larousserie

Université René Descartes - Paris 5, Lutetia Parisorum, Île-de-France, France

Are you Frédérique Larousserie?

Claim your profile

Publications (69)143.79 Total impact

  • [Show abstract] [Hide abstract]
    ABSTRACT: Extra-abdominal desmoid tumors are rare, locally aggressive neoplasms without metastatic potential. There is no clear consensus regarding their optimal management. The disappointing results of current treatments and the ability of extra-abdominal desmoid tumors to spontaneously stabilize have increasingly drawn interest toward conservative management. The objective of this study was to evaluate a wait-and-see policy as a first-line management for extra-abdominal desmoid tumors. This two-center retrospective study involved fifty-five patients with a histologically proven extra-abdominal desmoid tumor. The primary outcome was the cumulative probability of dropping out from the wait-and-see policy. The wait-and-see policy included aggressive management of symptoms. We conducted a review of the relevant published series in which a watchful-waiting strategy was used. The cumulative probability of dropping out from the wait-and-see policy was 9.6% at the time of the last follow-up. Spontaneous arrest of tumor growth was noted for forty-seven patients (85%) over the course of the study. Half of the tumors were stabilized at one year, and a potential to increase beyond three years was a sporadic event (one case). Regrowth was found in two patients (4%). A wait-and-see policy is an effective front-line management for patients with primary or recurrent extra-abdominal desmoid tumor. These tumors tend to stabilize spontaneously, on average after one year of evolution, and the cumulative probability of the failure of a wait-and-see policy is approximately 10%. Therapeutic Level IV. See Instructions for Authors for a complete description of levels of evidence.
    The Journal of Bone and Joint Surgery 04/2014; 96(8):631-8. DOI:10.2106/JBJS.M.00988 · 4.31 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Dedifferentiated liposarcoma (DDLPS) has been defined as a tumor composed of well-differentiated liposarcoma associated with a nonlipogenic undifferentiated sarcoma and is genetically characterized by a 12q13-15 amplicon with MDM2 amplification. Some peripheral (extremities, trunk wall, head/neck) undifferentiated pleomorphic sarcomas (UPS) without areas of well-differentiated liposarcoma present an MDM2 amplification. We addressed whether they are true DDLPS or not. We compared the clinical data, histologic data, MDM2 status (immunohistochemistry [IHC], fluorescence in situ hybridization [FISH]), genomic profile (array comparative genomic hybridization), and follow-up of 19 patients with peripheral UPS with MDM2 amplification and 62 with peripheral conventional DDLPS retrieved from the French sarcoma network (RRePS) and the Conticabase (Connective Tissue Cancer Network database). For a control cohort, we described 153 patients from the Conticabase, with peripheral UPS without expression of MDM2 by IHC. By IHC, tumor cells were positive for MDM2 in 59 conventional DDLPS and in all UPS with MDM2 amplification. FISH analysis and/or quantitative polymerase chain reaction showed amplification of MDM2 in 54 conventional DDLPS and in all UPS with MDM2 amplification. The 2-year overall survival rates of UPS with MDM2 amplification, conventional DDLPS, and UPS without expression of MDM2 were 93.3%, 90.7%, and 73.9%, respectively. Such similarities in the clinical characteristics, morphology, genomic profile, and follow-up of peripheral UPS with MDM2 amplification and peripheral conventional DDLPS strongly suggest that peripheral UPS with MDM2 amplification are in fact DDLPS. Faced with histologic diagnosis of UPS, a systematic IHC evaluation of MDM2 allows a selection of cases for FISH analysis permitting the diagnosis of DDLPS.
    The American journal of surgical pathology 03/2014; 38(3):293-304. DOI:10.1097/PAS.0000000000000131 · 4.59 Impact Factor
  • P. Anract, F. Larousserie, O. Mir, A. Feydy
    [Show abstract] [Hide abstract]
    ABSTRACT: Los condrosarcomas son tumores malignos primarios de estirpe condral. Se trata de un grupo heterogéneo de tumores que pueden caracterizarse por su localización en el hueso (central, o condrosarcoma convencional, o en la superficie del hueso, condrosarcoma propiamente dicho). Los tumores se distinguen por el aspecto histológico, además de la forma frecuente (donde existe diferenciación del tumor en cartílago hialino). Se observan condrosarcomas de células claras, desdiferenciados y mesenquimatosos. Además, se reconocen los formados a partir de una lesión cartilaginosa preexistente (osteocondroma o condroma), denominados «condrosarcomas secundarios». El condrosarcoma desarrollado sobre un osteocondroma también se conoce como «condrosarcoma periférico». Los condrosarcomas no son sensibles a la quimioterapia y son relativamente resistentes a la radioterapia. El tratamiento se basa en la resección quirúrgica. Estudios recientes de caracterización biológica permiten entrever posibilidades de tratamiento médico adyuvante.
    02/2014; 47(1):1–14. DOI:10.1016/S1286-935X(14)66938-0
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Much discussion about benign notochordal cell tissue in vertebrae has centered on the nature of its relationship, if any, to chordoma. Often referred to as benign notochordal cell tumors (BNCTs), these lesions have unique morphological features, however, differentiating between notochordal cells in discs, BNCT, and chordoma can be difficult. They are described as radiologically distinct from chordoma, with lysis, contrast enhancement, and a soft tissue mass indicating chordoma. All chordomas diagnosed at our institution, the Istituto Ortopedico Rizzoli (Bologna, Italy), prior to 2008 were reviewed, yielding 174 cases. Five were limited to bone; one was a recurrent chordoma without original data available. The remaining four were re-evaluated in detail. There were three women and one man, aged 33-57 years (mean, 48 years). Two were BNCTs and two were mixed lesions containing BNCT and chordoma. On computed tomography, all were radiopaque with areas of lysis. One BNCT was heterogeneous on magnetic resonance imaging, enhancing after contrast. Microscopically, one BNCT had a well-defined cystic area with a sclerotic border. The other had a minute atypical area; it recurred as chordoma. The mixed lesions had areas of definitive BNCT, definitive chordoma, and atypical areas that did not meet the criteria for either. The atypical areas in all three cases 'blended' with areas of chordoma or BNCT. These cases illustrate the ongoing challenges in differentiating between BNCT and chordoma. All had unique imaging features; three had atypical microscopic areas blending with BNCT or chordoma, strengthening the argument for a relationship between the two entities and supporting the idea that some BNCTs may progress to chordoma. Our study dispels the notion that any single radiologic criterion used to distinguish between chordoma and BNCT is reliable, opening the discussion as to whether or how to monitor BNCTs.
    Cancer imaging : the official publication of the International Cancer Imaging Society 01/2014; 14(1):4. DOI:10.1186/1470-7330-14-4 · 1.29 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: [This corrects the article on p. e75694 in vol. 8.].
    PLoS ONE 11/2013; 8(11). DOI:10.1371/annotation/e1a0e85e-e632-40f2-9925-e0b71eb18b56 · 3.53 Impact Factor
  • Frédérique Larousserie, Catherine Genestie
    [Show abstract] [Hide abstract]
    ABSTRACT: The histologic diagnosis of bone metastasis is often easy, based on tumor morphologic features on routine examination. The determination of the primary tumor is facilitated by ancillary techniques such as histochemical stainings and immunohistochemistry: it is possible, in about 65% of cases, with clinical correlation. Additional immunohistochemistry or molecular analyses are becoming more useful in various tumors (breast, lung, melanoma…) to give targeted therapy. From a technical point of view, bone is characterised by its difficulty to be sampled (with frequent crushing artifacts) and the necessity to decalcify samples with increase time of technique and frequent loss of nuclear markers antigenicity and difficulties in molecular analyses.
    Bulletin du cancer 11/2013; 100(11). DOI:10.1684/bdc.2013.1844 · 0.64 Impact Factor
  • D Vanel, F Larousserie
    11/2013; 94(11):1181. DOI:10.1016/j.diii.2013.10.008
  • D. Vanel, F. Larousserie
    11/2013; 94(11):1180. DOI:10.1016/j.jradio.2013.10.002
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Interleukin (IL)-27 is a cytokine of the IL-12 family that displays either immunostimulatory or immunosuppressive functions depending on the context. In various murine tumor models including melanoma models, ectopic expression of IL-27 has been shown to play an anti-tumoral role and to favor tumor regression. In this study, we investigated whether IL-27 might play a role in the development of melanoma in humans. We analyzed the in situ expression of IL-27 in melanocytic lesions (n = 82) representative of different stages of tumor progression. IL-27 expression was not observed in nevus (n = 8) nor in in situ melanoma (n = 9), but was detected in 28/46 (61%) cases of invasive cutaneous melanoma, notably in advanced stages (19/23 cases of stages 3 and 4). In most cases, the main source of IL-27 was tumor cells. Of note, when IL-27 was detected in primary cutaneous melanomas, its expression was maintained in metastatic lesions. These in situ data suggested that the immunosuppressive functions of IL-27 may dominate in human melanoma. Consistent with this hypothesis, we found that IL-27 could induce suppressive molecules such as PD-L1, and to a lesser extent IL-10, in melanoma cells, and that the in situ expression of IL-27 in melanoma correlated with those of PD-L1 and IL-10.
    PLoS ONE 10/2013; 8(10):e75694. DOI:10.1371/journal.pone.0075694 · 3.53 Impact Factor
  • Frédérique Larousserie
    Annales de Pathologie 08/2013; 33(4):255-8. DOI:10.1016/j.annpat.2013.06.001 · 0.29 Impact Factor
  • G. Riouallon, F. Larousserie, E. Pluot, P. Anract
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Les myxofibrosarcomes superficiels sont des tumeurs conjonctives malignes, dont les récidives, extrêmement fréquentes, mettent en jeu le pronostic local et général. Même lorsque l’exérèse chirurgicale semble complète macroscopiquement, elle est très souvent microscopiquement contaminée. Le but de ce travail était d’évaluer la récidive en fonction des marges de résection et de comparer, quand cela était possible, la taille de la lésion évaluée cliniquement et macroscopiquement par l’anatomopathologiste. Patients et méthodes Il s’agit d’une série rétrospective monocentrique composée de 21 patients, d’un âge moyen de 67 ans, pris en charge pour un myxofibrosarcome superficiel. Le nombre, la date et la localisation des récidives ont été colligés pour chaque patient. Pour chaque récidive, le plus grand axe de la tumeur a été évalué cliniquement et à l’examen anatomopathologique. Résultats Cinquante-sept pour cent des patients ont présenté une récidive. Le nombre moyen de récidives était de 1,4 par patient (1 à 8). Les marges de résection étaient saines dans quatre cas, marginales dans deux cas et incomplètes pour les 15 autres patients avec des taux de récidives respectifs de 25, 50 et 67 %. La taille évaluée à l’examen clinique préopératoire (14 cas) était sous-estimée en moyenne de 2,4 cm par rapport à la taille évaluée par l’examen macroscopique anatomopathologique. La taille évaluée sur l’IRM préopératoire (5 cas) était également sous-estimée de 1,3 cm en moyenne. Conclusion Les myxofibrosarcomes superficiels sont des tumeurs difficiles à réséquer complètement d’emblée en raison de leur caractère infiltrant, souvent sous-estimé avant l’intervention. Leur traitement chirurgical nécessite des marges de résection beaucoup plus larges que ne le laissent prévoir l’évaluation clinique et l’IRM. En cas de résection incomplète, la reprise cicatricielle doit être faite systématiquement. Niveau de preuve IV. Étude rétrospective.
    Revue de Chirurgie Orthopédique et Traumatologique 06/2013; 99(4):390–395. DOI:10.1016/j.rcot.2012.12.008
  • G Riouallon, F Larousserie, E Pluot, P Anract
    [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Superficial myxofibrosarcomas are malignant connective tissue tumors, whose very frequent recurrence influences the local and vital prognosis. Even when resection seems to be macroscopically complete it is very often microscopically contaminated. The aim of this study was to evaluate recurrence in relation to the surgical margins and to compare, when possible, tumor size, evaluated clinically and macroscopically by the pathologist. MATERIALS AND METHODS: This was a single center study of 21 patients, mean age 67 years old, treated for superficial myxofibrosarcoma. The number, date and location of recurrence were collected for each patient. A clinical and pathological measurement was made of the longest axis of the tumor in each case of recurrence. RESULTS: Fifty-seven percent of patients presented with recurrent tumors. The mean number of recurrences was 1.4 per patient (1-8). The surgical margins were wide in four cases, marginal in two cases and incomplete/intralesional in 15 other patients with a rate of recurrence of 25, 50 and 67% respectively. The size evaluated during the preoperative clinical examination (14 cases) was underestimated by a mean 2.4cm compared to the macroscopic pathology assessment. The preoperative size on MRI (5 cases) was also underestimated by a mean 1.3cm. CONCLUSION: Superficial myxofibrosarcomas are tumors that are difficult to resect completely because they are infiltrative, a feature that is often underestimated before surgery. Surgical treatment of this entity requires a much larger surgical margin than that suggested by the preoperative clinical and MRI evaluations. In case of incomplete resection, revision scar surgery should systematically be performed. LEVEL OF EVIDENCE: Level IV. Retrospective study.
    Orthopaedics & Traumatology Surgery & Research 04/2013; 99(4). DOI:10.1016/j.otsr.2012.11.020 · 1.17 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: GNAS (guanine nucleotide-binding protein/α-subunit) mutations that induce the activation of G-protein α-subunit participate in the pathogenesis of fibrous dysplasia. The aim of this study was to evaluate the sensitivity and specificity of GNAS mutations in fibrous dysplasia and other fibro-osseous lesions, to assess the value of investigating this mutation in the diagnosis of fibro-osseous lesions. We studied 91 cases of fibrous dysplasia. The quality and/or quantity of genomic DNA were suitable for molecular analysis for 51 cases of fibrous dysplasia. GNAS mutations were investigated by three techniques: high-resolution melting (exon 8), allele-specific PCR (exons 8 and 9) and/or direct DNA sequencing (exons 8 and 9). Fibrous dysplasia samples were classified blind to the GNAS mutation status into six histological subtypes as conventional, fibro-involutive, osteosclerosing, cementifying, osteocartilaginous and with prominent aneurysmal cystic changes. We also studied 14 cases of low-grade osteosarcoma, 21 cases of ossifying fibroma, 3 cases of osteofibrous dysplasia, 1 case of osseous dysplasia of the jawbone and 1 post-traumatic lesion of the ribs. Twenty-three cases of fibrous dysplasia (45%) showed mutations of codon 201 (exon 8, p.R201H or p.R201C). No mutation was found on codon 227 (exon 9). GNAS mutations in conventional fibrous dysplasia were detected in the same proportion (47%) as in the other histological subtypes (47%, P=0.96), regardless of sex (P=0.44), age (P=0.90) and location (P=1). GNAS mutations were not detected in any other fibro-osseous lesions. The GNAS mutation was thus specific to fibrous dysplasia in the context of fibro-osseous lesions. The particular mosaicism of mutant and non-mutant cells within the lesion or the existence of other mutations not already described could explain the lack of GNAS mutation in cases of fibrous dysplasia. Investigating this mutation may constitute a valuable complementary diagnostic tool, despite its low sensitivity, particularly in unconventional morphologically different subtypes of fibrous dysplasia.
    Modern Pathology 02/2013; 26. DOI:10.1038/modpathol.2012.223 · 6.36 Impact Factor
  • Frédérique Larousserie
    Annales de Pathologie 01/2013; 33(4):255–258. · 0.29 Impact Factor
  • Revue de Chirurgie Orthopédique et Traumatologique 11/2012; 98(7):S378-S379. DOI:10.1016/j.rcot.2012.08.262
  • Annals of Oncology 03/2012; 23(3):807-9. DOI:10.1093/annonc/mds005 · 6.58 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Alveolar soft part sarcoma is a rare malignancy usually considered resistant to conventional chemotherapy, but recent data suggest that the multikinase inhibitors sunitinib and cediranib could be active in this setting. A 90-year-old lady with alveolar soft part sarcoma of the leg and lung metastases was started on sunitinib 37.5 mg daily. The treatment was poorly tolerated with grade 3 hypertension and grade 3 thrombocytopenia, which persisted after dose reduction to 25 mg daily. The patient was subsequently started on bevacizumab 10 mg/kg every 2 weeks, resulting in a marked improvement in pain and a partial response on lung metastases for 16 months and ongoing. Agents targeting the vascular endothelial growth factor-signalling pathway seem to exert clinically relevant and prolonged activity against alveolar soft part sarcoma and deserve further evaluation in the treatment of this rare soft tissue sarcoma.
    Anti-cancer drugs 02/2012; 23(7):745-8. DOI:10.1097/CAD.0b013e3283514b8c · 1.89 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: Primary bone tumors are rare and require a multidisciplinary approach. Diagnosis involves primarily the radiologist and the pathologist. Bone lesions are often heterogeneous and the microscopic diagnostic component(s) may be in the minority, especially on core needle biopsies. Reactive processes, benign, and malignant tumors may have similar microscopic aspects. For these challenging cases, the correlation of microscopic and radiologic information is critical, or diagnostic mistakes may be made with severe clinical consequences for the patient. The purpose of this article is to explain how pathologists can best use imaging studies to improve the diagnostic accuracy of bone lesions. DIAGNOSIS: Many bone lesions are microscopically and/or radiographically heterogeneous, especially those with both lytic and matrix components. Final diagnosis may require specific microscopic diagnostic features that may be present in the lesion, but not the biopsy specimen. A review of the imaging helps assess if sampling was adequate. The existence of a pre-existing bone lesion, syndrome (such as Ollier disease or multiple hereditary exostosis), or oncologic history may be of crucial importance. Finally, imaging information is very useful for the pathologist to perform accurate local and regional staging during gross examination. CONCLUSION: Close teamwork between pathologists, radiologists, and clinicians is of utmost importance in the evaluation and management of bone tumors. These lesions can be very difficult to interpret microscopically; imaging studies therefore play a crucial role in their accurate diagnosis.
    European journal of radiology 01/2012; 82(12). DOI:10.1016/j.ejrad.2011.11.037 · 2.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: INTRODUCTION: There is no clear radiologic or pathologic agreement on the differences between enchondroma and conventional chondrosarcoma, which has huge therapeutic consequences. Microscopically, an enchondroma is composed of "islands of intramedullary hyaline cartilage surrounded by marrow fat", and a chondrosarcoma a "diffuse cartilaginous replacement (invasion) of the marrow which leads to complete 'trapping' of host lamellar bone trabeculae." The marrow around islands of cartilage should be detectable on magnetic resonance imaging (MR). Enchondroma may be the precursor of chondrosarcoma; benign cartilaginous islands are often seen microscopically at the periphery of chondrosarcoma. We attempted to detect these islands at the periphery of chondrosarcomas on MR and correlate them microscopically. MATERIALS AND METHODS: We examined our database for all patients with a chondrosarcoma of the long and flat bones between 1990 and 2007. Only those with a preoperative MR who underwent an en bloc resection were included, yielding 32 patients. We looked for low-signal islands surrounded by high (fat) signal on T1-weighted images, and high-signal islands surrounded by low signal on T2-weighted fat saturated images at the periphery of the main tumour mass. Microscopic correlation was performed in all cases. RESULTS: On microscopy, there were 23 conventional chondrosarcomas, nine dedifferentiated. Peripheral islands surrounded by fat were detected on MR in 19 cases, corresponding to benign cartilage in 18 cases and to the benign scar of a needle biopsy tract in one. There were no peripheral islands detected radiographically or microscopically in 13 cases. CONCLUSION: Cartilaginous islands microscopically detected at the periphery of some chondrosarcomas are easily and reliably diagnosed on MR.
    European journal of radiology 01/2012; 82(12). DOI:10.1016/j.ejrad.2011.11.043 · 2.16 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The interpretation of a biopsy specimen involving bone is one of the most challenging feats for a pathologist, as it is often difficult to distinguish between benign or reactive lesions and malignant tumors on microscopic analysis. Therefore, correlation with the clinical data and imaging is essential and sometimes it is only the evolution of certain characteristics over time or information garnered from molecular analysis that can provide an accurate diagnosis. The pathology report is critical in that it will define subsequent patient management; its wording must precisely reflect those elements that are known with certainty and those that are diagnostic hypotheses. It must be systematic, thorough, and complete and should not be limited to a simple conclusion. The pathologist must first ensure the completeness and correct transcription of the information provided with the specimen, then describe and analyze the histology as well as the quality and representative nature of the sample (as they relate to the radiographic findings and preliminary/final diagnoses), and finally, compare what is seen under the microscope with the assessment made by the radiologist and/or surgeon. This analysis helps to identify difficult cases requiring further consultation between the radiologist and pathologist. There are multiple reasons for misinterpretation of a pathology report. An important and largely underestimated reason is varied interpretations of terms used by the pathologist. Standardized pathology reports with concise phrases as well as multidisciplinary meetings may limit errors and should be encouraged for optimal diagnostic accuracy.
    European journal of radiology 01/2012; 82(12). DOI:10.1016/j.ejrad.2011.11.036 · 2.16 Impact Factor

Publication Stats

550 Citations
143.79 Total Impact Points


  • 2009–2014
    • Université René Descartes - Paris 5
      • • Faculty of medicine
      • • Département de Parodontologie
      • • Faculté de Médecine
      Lutetia Parisorum, Île-de-France, France
  • 2013
    • Université Paris-Sorbonne - Paris IV
      Lutetia Parisorum, Île-de-France, France
  • 2012
    • Istituto Ortopedico Rizzoli
      Bolonia, Emilia-Romagna, Italy
  • 2010
    • CHRU de Strasbourg
      Strasburg, Alsace, France
  • 2008
    • Hôpital Paris Saint Joseph
      Lutetia Parisorum, Île-de-France, France
  • 2006–2007
    • French National Centre for Scientific Research
      Lutetia Parisorum, Île-de-France, France
  • 2005–2007
    • Assistance Publique – Hôpitaux de Paris
      Lutetia Parisorum, Île-de-France, France